JPWO2023210741A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023210741A5 JPWO2023210741A5 JP2024518025A JP2024518025A JPWO2023210741A5 JP WO2023210741 A5 JPWO2023210741 A5 JP WO2023210741A5 JP 2024518025 A JP2024518025 A JP 2024518025A JP 2024518025 A JP2024518025 A JP 2024518025A JP WO2023210741 A5 JPWO2023210741 A5 JP WO2023210741A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- methyl
- dihydro
- ethyl
- benzotriazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 25
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 21
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 21
- 235000019260 propionic acid Nutrition 0.000 claims 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- -1 2-hydroxy-2-methylpropyl group Chemical group 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 10
- 230000005855 radiation Effects 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 208000010412 Glaucoma Diseases 0.000 claims 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000037380 skin damage Effects 0.000 claims 5
- 208000024412 Friedreich ataxia Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 3
- 101150116862 KEAP1 gene Proteins 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000004850 protein–protein interaction Effects 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000016134 Conjunctival disease Diseases 0.000 claims 1
- 206010010755 Conjunctivitis viral Diseases 0.000 claims 1
- 206010061788 Corneal infection Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020524 Hydronephrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000035556 autoimmune disorder of central nervous system Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 150000001924 cycloalkanes Chemical group 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 206010062952 diffuse panbronchiolitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 206010023365 keratopathy Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000038015 macular disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022075223 | 2022-04-28 | ||
| JP2022075223 | 2022-04-28 | ||
| PCT/JP2023/016629 WO2023210741A1 (ja) | 2022-04-28 | 2023-04-27 | ベンゾトリアゾール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023210741A1 JPWO2023210741A1 (https=) | 2023-11-02 |
| JPWO2023210741A5 true JPWO2023210741A5 (https=) | 2024-11-26 |
| JP7605446B2 JP7605446B2 (ja) | 2024-12-24 |
Family
ID=88518776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518025A Active JP7605446B2 (ja) | 2022-04-28 | 2023-04-27 | ベンゾトリアゾール化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20250282724A1 (https=) |
| EP (1) | EP4509504A4 (https=) |
| JP (1) | JP7605446B2 (https=) |
| KR (1) | KR20250004844A (https=) |
| CN (1) | CN119173511A (https=) |
| AU (1) | AU2023259936A1 (https=) |
| CA (1) | CA3256688A1 (https=) |
| CO (1) | CO2024014914A2 (https=) |
| IL (1) | IL316449A (https=) |
| MX (1) | MX2024013242A (https=) |
| TW (1) | TW202404984A (https=) |
| WO (1) | WO2023210741A1 (https=) |
| ZA (1) | ZA202408061B (https=) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8796447B2 (en) | 2009-08-21 | 2014-08-05 | Otsuka Pharmaceutical Co., Ltd. | Process for producing benzo[B][1,4]diazepine-2,4-dione compound |
| BR112013026341A2 (pt) | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| AU2014253275B2 (en) | 2013-04-11 | 2018-10-18 | F. Hoffmann-La Roche Ag | BACE1 inhibitors |
| KR102301867B1 (ko) | 2013-12-18 | 2021-09-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| AU2015266453C1 (en) | 2014-05-30 | 2018-09-13 | Shanghai Emerald Wellcares Pharmaceutical Co., Ltd | Alk kinase inhibitor, and preparation method and use thereof |
| SI3782996T1 (sl) | 2015-06-15 | 2024-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulatorji |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| EP3766878B1 (en) | 2015-06-15 | 2022-03-16 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのビスアリール複素環 |
| JP2020502136A (ja) * | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのビスアリールアミド |
| EP3555068B1 (en) | 2016-12-14 | 2020-12-02 | GlaxoSmithKline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| CA3044773A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| JP2020097526A (ja) | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021524469A (ja) | 2018-05-23 | 2021-09-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのインダン |
| CA3102996A1 (en) * | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| HUE065501T2 (hu) | 2018-08-20 | 2024-05-28 | Janssen Pharmaceutica Nv | A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok |
| JP7602469B2 (ja) | 2019-02-15 | 2024-12-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン |
| EP3953337A4 (en) | 2019-04-08 | 2023-08-09 | Dana-Farber Cancer Institute, Inc. | Degraders of kelch-like ech-associated protein 1 (keap1) |
| MX2021014680A (es) | 2019-05-31 | 2022-04-06 | Ube Corp | Derivado de benzotriazol. |
| CN114080389B (zh) | 2019-07-03 | 2024-08-30 | 千寿制药株式会社 | Nrf2活性化化合物 |
-
2023
- 2023-04-27 JP JP2024518025A patent/JP7605446B2/ja active Active
- 2023-04-27 WO PCT/JP2023/016629 patent/WO2023210741A1/ja not_active Ceased
- 2023-04-27 US US18/860,540 patent/US20250282724A1/en active Pending
- 2023-04-27 CA CA3256688A patent/CA3256688A1/en active Pending
- 2023-04-27 CN CN202380036607.2A patent/CN119173511A/zh active Pending
- 2023-04-27 TW TW112115867A patent/TW202404984A/zh unknown
- 2023-04-27 EP EP23796477.0A patent/EP4509504A4/en active Pending
- 2023-04-27 KR KR1020247038642A patent/KR20250004844A/ko active Pending
- 2023-04-27 IL IL316449A patent/IL316449A/en unknown
- 2023-04-27 AU AU2023259936A patent/AU2023259936A1/en active Pending
-
2024
- 2024-10-24 ZA ZA2024/08061A patent/ZA202408061B/en unknown
- 2024-10-25 MX MX2024013242A patent/MX2024013242A/es unknown
- 2024-10-25 US US18/927,756 patent/US12378260B2/en active Active
- 2024-10-31 CO CONC2024/0014914A patent/CO2024014914A2/es unknown
-
2025
- 2025-06-30 US US19/255,689 patent/US20250326770A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7591066B2 (ja) | Ｌｐａ受容体アンタゴニスト及びそれらの使用 | |
| US11584738B2 (en) | LPA receptor antagonists and uses thereof | |
| CN106061978B (zh) | 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶 | |
| RU2655914C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP5820056B2 (ja) | Ｃｅｔｐ阻害剤としてのシクロアルケニルアリール誘導体 | |
| AU2008314963A1 (en) | Oxadiazolidinedione compound | |
| JP7476216B2 (ja) | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 | |
| CN106795147B (zh) | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 | |
| RU2005125209A (ru) | Производные пирролопиридазина | |
| JP2013542937A5 (https=) | ||
| CN102112453A (zh) | 新的钾通道阻断剂及其用途 | |
| JPWO2010001946A1 (ja) | トリアゾール誘導体またはその塩 | |
| KR20190129034A (ko) | 금속효소 억제제 화합물 | |
| JP2020503332A5 (https=) | ||
| RU2746001C2 (ru) | Производные 3-(6-хлор-3-оксо-3,4-дигидро-(2h)-1,4-бензоксазин-4-ил)пропионовой кислоты и их применение в качестве ингибиторов kmo | |
| JP7494222B2 (ja) | ピリジン－３－イル誘導体 | |
| JPWO2023210741A5 (https=) | ||
| JP7048601B2 (ja) | ｍＧｌｕＲ７調節疾患、障害、または病状を処置するためのｍＧｌｕＲ７アゴニスト化合物 | |
| JPWO2023210740A5 (https=) | ||
| AU2015367396B2 (en) | 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors | |
| RU2024129723A (ru) | Соединение бензотриазола | |
| CN111936488A (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| CA3185689C (en) | Lpa receptor antagonists and uses thereof | |
| JP7618898B1 (ja) | ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬 | |
| HK40088982B (zh) | Lpa受体拮抗剂及其用途 |